Mie K. Eickhoff
YOU?
Author Swipe
View article: Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate
Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate Open
Sodium–glucose cotransporter 2 (SGLT2) inhibitors can cause a reversible decline in glomerular filtration rate (GFR), which may influence dosing recommendations for renally excreted medications. In practice, GFR is typically estimated by s…
View article: Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort
Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort Open
View article: Performance of new and panel <scp>CKD‐EPI</scp> equations in European adults with type 2 diabetes
Performance of new and panel <span>CKD‐EPI</span> equations in European adults with type 2 diabetes Open
Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D) characterized by albuminuria and a progressive decline in the glomerular filtration rate (GFR).1 CKD in the setting of T2D can be the result of diabetic nephrop…
View article: Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease Open
The current study discovers the urinary proteome impacted by the SGLT2i, thereby providing new potential target sites and pathways, especially relating to wound healing and inflammation.
View article: Dapagliflozin improves the urinary proteomic kidney risk classifier CKD273 in type 2 diabetes with albuminuria – a randomized clinical trial
Dapagliflozin improves the urinary proteomic kidney risk classifier CKD273 in type 2 diabetes with albuminuria – a randomized clinical trial Open
Objective: To evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin, on the kidney risk urinary proteomic classifier (CKD273), in persons with type 2 diabetes and albuminuria. Researc…
View article: Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial
Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial Open
OBJECTIVE To evaluate the effect of the sodium–glucose cotransporter 2 inhibitor dapagliflozin on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria. RESEARCH DESIGN AND METHODS In a…
View article: Dapagliflozin improves the urinary proteomic kidney risk classifier CKD273 in type 2 diabetes with albuminuria – a randomized clinical trial
Dapagliflozin improves the urinary proteomic kidney risk classifier CKD273 in type 2 diabetes with albuminuria – a randomized clinical trial Open
Objective: To evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin, on the kidney risk urinary proteomic classifier (CKD273), in persons with type 2 diabetes and albuminuria. Researc…
View article: Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor Open
Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decre…
View article: Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions
Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions Open
Background The glycocalyx is an extracellular layer lining the lumen of the vascular endothelium, protecting the endothelium from shear stress and atherosclerosis and contributes to coagulation, immune response and microvascular perfusion.…
View article: Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial Open
View article: Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors Open
Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart and kidney failure in patients with type 2 diabetes, possibly due to diuretic effects. Previous non-placebo-controlled studies with SGLT2 inhibitors observed chang…
View article: SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY
SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY Open
RESULTS: 523 patients included 391 men(74.8%),mean age 62612 years, mean serum creatinine 2.762.2mg/ dl, glycosylated hemoglobin 761.7% and proteinuria 3.2 (1.5-6) gr/24h.In the renal biopsy, 36% had DN, 53% NDN and 11% DN and NDN.35.2% (n…